231 related articles for article (PubMed ID: 32946168)
1. 1,3,4-oxadiazole and its derivatives: A review on recent progress in anticancer activities.
Vaidya A; Pathak D; Shah K
Chem Biol Drug Des; 2021 Mar; 97(3):572-591. PubMed ID: 32946168
[TBL] [Abstract][Full Text] [Related]
2. Groundbreaking Anticancer Activity of Highly Diversified Oxadiazole Scaffolds.
Benassi A; Doria F; Pirota V
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33217987
[TBL] [Abstract][Full Text] [Related]
3. 1,3,4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents.
Bajaj S; Asati V; Singh J; Roy PP
Eur J Med Chem; 2015 Jun; 97():124-41. PubMed ID: 25965776
[TBL] [Abstract][Full Text] [Related]
4. 1,3,4-Oxadiazole Containing Compounds As Therapeutic Targets For Cancer Therapy.
Ahsan MJ
Mini Rev Med Chem; 2022; 22(1):164-197. PubMed ID: 33634756
[TBL] [Abstract][Full Text] [Related]
5. 1,3,4-oxadiazole-2-thione Derivatives; Novel Approach for Anticancer and Tubulin Polymerization Inhibitory Activities.
Abdel-Aziz M; Metwally KA; Gamal-Eldeen AM; Aly OM
Anticancer Agents Med Chem; 2015; 16(2):269-77. PubMed ID: 26343141
[TBL] [Abstract][Full Text] [Related]
6. Rationale Design, Synthesis, Cytotoxicity Evaluation, and Molecular Docking Studies of 1,3,4-oxadiazole Analogues.
Ahsan MJ; Choupra A; Sharma RK; Jadav SS; Padmaja P; Hassan MZ; Al-Tamimi ABS; Geesi MH; Bakht MA
Anticancer Agents Med Chem; 2018; 18(1):121-138. PubMed ID: 28425854
[TBL] [Abstract][Full Text] [Related]
7. The Development of HDAC and Tubulin Dual-Targeting Inhibitors for Cancer Therapy.
Nie J; Wu H; Luan Y; Wu J
Mini Rev Med Chem; 2024; 24(5):480-490. PubMed ID: 37461341
[TBL] [Abstract][Full Text] [Related]
8. Developments of combretastatin A-4 derivatives as anticancer agents.
Shan Y; Zhang J; Liu Z; Wang M; Dong Y
Curr Med Chem; 2011; 18(4):523-38. PubMed ID: 21143124
[TBL] [Abstract][Full Text] [Related]
9. Substituted oxadiazoles: a patent review (2010 - 2012).
Zarghi A; Hajimahdi Z
Expert Opin Ther Pat; 2013 Sep; 23(9):1209-32. PubMed ID: 23663160
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity.
Pidugu VR; Yarla NS; Pedada SR; Kalle AM; Satya AK
Bioorg Med Chem; 2016 Nov; 24(21):5611-5617. PubMed ID: 27665180
[TBL] [Abstract][Full Text] [Related]
11. Recent Applications of Benzimidazole as a Privileged Scaffold in Drug Discovery.
Guo Y; Hou X; Fang H
Mini Rev Med Chem; 2021; 21(11):1367-1379. PubMed ID: 32753010
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the synthesis of tubulysins.
Xiangming X; Friestad GK; Lei Y
Mini Rev Med Chem; 2013 Oct; 13(11):1572-8. PubMed ID: 23746060
[TBL] [Abstract][Full Text] [Related]
13. Biological activity of oxadiazole and thiadiazole derivatives.
Atmaram UA; Roopan SM
Appl Microbiol Biotechnol; 2022 May; 106(9-10):3489-3505. PubMed ID: 35562490
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, quantitative structure-activity relationship and biological evaluation of 1,3,4-oxadiazole derivatives possessing diphenylamine moiety as potential anticancer agents.
Abdel Rahman DE
Chem Pharm Bull (Tokyo); 2013; 61(2):151-9. PubMed ID: 23370194
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities.
Zhu H; Li W; Shuai W; Liu Y; Yang L; Tan Y; Zheng T; Yao H; Xu J; Zhu Z; Yang DH; Chen ZS; Xu S
Eur J Med Chem; 2021 Apr; 216():113316. PubMed ID: 33676300
[TBL] [Abstract][Full Text] [Related]
16. Oxadiazole: A highly versatile scaffold in drug discovery.
Desai N; Monapara J; Jethawa A; Khedkar V; Shingate B
Arch Pharm (Weinheim); 2022 Sep; 355(9):e2200123. PubMed ID: 35575467
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
Yang Z; Shen M; Tang M; Zhang W; Cui X; Zhang Z; Pei H; Li Y; Hu M; Bai P; Chen L
Eur J Med Chem; 2019 Sep; 178():116-130. PubMed ID: 31177073
[TBL] [Abstract][Full Text] [Related]
18. Indolyl-α-keto-1,3,4-oxadiazoles: Synthesis, anti-cell proliferation activity, and inhibition of tubulin polymerization.
Tantak MP; Malik M; Klingler L; Olson Z; Kumar A; Sadana R; Kumar D
Bioorg Med Chem Lett; 2021 Apr; 37():127842. PubMed ID: 33556575
[TBL] [Abstract][Full Text] [Related]
19. Identification of diaryl 5-amino-1,2,4-oxadiazoles as tubulin inhibitors: the special case of 3-(2-fluorophenyl)-5-(4-methoxyphenyl)amino-1,2,4-oxadiazole.
Gakh AA; Sosnov AV; Krasavin M; Nguyen TL; Hamel E
Bioorg Med Chem Lett; 2013 Mar; 23(5):1262-8. PubMed ID: 23385208
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, biological evaluation, and 3D-QSAR analysis of podophyllotoxin-dioxazole combination as tubulin targeting anticancer agents.
Wang ZZ; Sun WX; Wang X; Zhang YH; Qiu HY; Qi JL; Pang YJ; Lu GH; Wang XM; Yu FG; Yang YH
Chem Biol Drug Des; 2017 Aug; 90(2):236-243. PubMed ID: 28079286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
